Pharma BD Deal Intelligence
Cerevel Therapeutics, the 2018 Pfizer-Bain Capital neuroscience spin-out, completed a SPAC merger with ARYA Sciences Acquisition Corp II raising $445M and listing on Nasdaq at ~$1.3B valuation. Pfizer retained equity stake. Pipeline included tavapadon for Parkinson's, CVL-231 for schizophrenia, and darigabat for epilepsy/anxiety. Post-close arc: the platform thesis largely played out. In April 2024 lead Parkinson's asset tavapadon hit its primary endpoint in the Phase 3 adjunctive TEMPO-3 trial. On August 1, 2024 AbbVie completed its acquisition of Cerevel for $45.00 per share (announced December 6, 2023; ~$8.7B equity value) — roughly a 6.7x step-up from the 2020 ~$1.3B SPAC valuation. However, in November 2024 AbbVie disclosed that emraclidine (CVL-231), the M4 PAM that carried the bulk of the pipeline's expected value, failed both Phase 2 EMPOWER schizophrenia trials, showing no statistically significant PANSS separation from placebo — a material impairment to the deal's central schizophrenia thesis.
Assessment window: 5yr post-close.